Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer
Related Experiment Video
Updated: Jul 12, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Izuru Watanabe1, Hideki Kasuya, Naohiro Nomura
1Department of Surgery II, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
Purpose:
Pancreatic cancer still has a poor prognosis, even if aggressive therapy is pursued. Currently, new modalities of oncolytic virus therapy are being tested against this cancer. The combination of one of two representative mutant herpes simplex viruses (R3616: gamma(1)34.5 inactivated, hrR3: UL39 inactivated) with a standard anti-pancreatic cancer chemotherapy drug (gemcitabine), was investigated in this study.
Experimental Design:
The intracellular concentration of ribonucleotide reductase was estimated by Western blotting. The effect of gemcitabine on viral replication and the total cytotoxic effect of the combination therapy were investigated on pancreatic cancer cell lines. We compared the results of two oncolytic viruses, R3616 and hrR3. A mouse model of pancreatic cancer with peritoneal dissemination was used to evaluate the in vivo effect of the combination therapy.
Results:
Although the replication of both viruses was inhibited by gemcitabine, the combination caused more tumor cell cytotoxicity than did virus alone in vitro. The results with R3616 were more striking. Although the difference was not statistically significant, R3616 with gemcitabine had a greater effect than did R3616 alone, while hrR3 with gemcitabine had a weaker effect than did hrR3 alone in vivo experiments.
Conclusion:
The combination of oncolytic virus with gemcitabine is a promising new strategy against advanced pancreatic cancer. Each virus has different functional characteristics, and can affect the results of the combination of viruses and chemotherapy drugs. The results indicate that there is a complicated interaction among viruses, cells, and chemotherapy drugs and that the best combination of oncolytic virus and chemotherapeutic agents should be studied more extensively before embarking on a clinical trial.
Insights
Combining oncolytic viruses with gemcitabine shows promise for pancreatic cancer. Different herpes simplex virus strains yield varied results, highlighting complex interactions for future clinical trials.
Area of Science:
- Oncology
- Virology
- Cancer Therapy
Background:
- Pancreatic cancer presents a poor prognosis despite aggressive treatments.
- Oncolytic virus therapy is an emerging treatment modality for pancreatic cancer.
Purpose of the Study:
- To investigate the combination of two mutant herpes simplex viruses (R3616 and hrR3) with gemcitabine for pancreatic cancer treatment.
- To compare the efficacy of two distinct oncolytic viruses in combination with chemotherapy.
Main Methods:
- Western blotting was used to assess intracellular ribonucleotide reductase concentration.
- In vitro studies on pancreatic cancer cell lines evaluated gemcitabine's effect on viral replication and combination therapy cytotoxicity.
- In vivo studies utilized a mouse model of pancreatic cancer with peritoneal dissemination.
Main Results:
- Gemcitabine inhibited viral replication but combination therapy enhanced tumor cell cytotoxicity in vitro.
- The R3616 virus combined with gemcitabine showed a more pronounced effect than the virus alone.
- In vivo, R3616 with gemcitabine demonstrated a greater effect than R3616 alone, while hrR3 with gemcitabine showed a weaker effect than hrR3 alone.
Conclusions:
- Combination therapy of oncolytic viruses and gemcitabine is a promising strategy for advanced pancreatic cancer.
- The distinct characteristics of each virus influence combination therapy outcomes.
- Further extensive research is needed to determine optimal virus-chemotherapy combinations before clinical trials.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...